更新于：2024-11-18
Fosfomycin Tromethamine
磷霉素氨丁三醇
更新于：2024-11-18
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1988-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C7H18NO7P |
InChIKeyQZJIMDIBFFHQDW-LMLSDSMGSA-N |
CAS号78964-85-9 |
关联
27
项与 磷霉素氨丁三醇 相关的临床试验江苏联环药业股份有限公司研制的磷霉素氨丁三醇颗粒（3 g）与Zambon Switzerland Ltd.生产的磷霉素氨丁三醇颗粒（3 g）在中国健康受试者中进行的随机、开放、单剂量、两序列、两周期、交叉、空腹状态下的生物等效性研究
Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic Prophylaxis for Urinary Tract Infection Prevention in Post-Urodynamic Examination
A Multicentric, Randomized, Open Label, Controlled, Phase III Clinical Trial to evaluate theEfficacy, Safety and Tolerability of Fosfomycin (Trometamol) Powder 3 g versusCiprofloxacin Tablets 750 mg in patients with Chronic Bacterial Prostatitis and Chronic Pelvic Pain Syndrome
100 项与 磷霉素氨丁三醇 相关的临床结果
登录后查看更多信息
100 项与 磷霉素氨丁三醇 相关的转化医学
登录后查看更多信息
100 项与 磷霉素氨丁三醇 相关的专利（医药）
登录后查看更多信息
251
项与 磷霉素氨丁三醇 相关的文献（医药）2024-03-01The Journal of hospital infection
Comparison of different regimens of short-term antibiotic prophylaxis in transrectal prostate biopsy
Article
作者: Krsakova, E ; Cermak, A ; Fedorko, M
BACKGROUND:
Prostate cancer is the most common malignant solid tumour in men aged >70 years and is the second most common cause of death from oncological circumstances.
AIM:
To evaluate the effect of different short-term prophylactic antibiotic regimens in transrectal prostate biopsy (PB) on the incidence of infectious complications.
METHODS:
Patients who underwent transrectal ultrasound-guided PB between January 2021 and December 2022 were included in the prospective randomized study. According to the regimen of prophylaxis, patients were randomized into three groups: (1) fosfomycin trometamol 3 g, 3 h before the procedure + ciprofloxacin 500 mg, 2 h before the procedure; (2) fosfomycin trometamol 3 g, 3 h before and 24 h after the procedure; (3) ciprofloxacin 500 mg 12, 2 h before the procedure, and 12 h after the procedure. A rectal swab was performed 1-2 weeks before PB to evaluate the culture findings. Complications were evaluated during follow-up visits within one month after PB.
FINDINGS:
In the monitored period, 605 PBs were performed, and 544 patients met the inclusion criteria (184, 161, and 199 in groups 1, 2, and 3). Infectious complications occurred in 10 cases (1.83%), namely 3, 4, and 3 according to patient groups. There was no statistically significant difference between the individual groups. None of the patients required hospitalization and all were free of symptoms of sepsis.
CONCLUSION:
Short-term antibiotic prophylaxis in PB using fosfomycin trometamol, ciprofloxacin, or their combination appears to be effective. Fosfomycin trometamol is a suitable alternative to fluoroquinolone antibiotics.
2023-12-27Urologiia (Moscow, Russia : 1999)
Optimization of prevention of infectious complications during prostate biopsy
Review
作者: Kolontarev K, B ; Pushkar D, Yu ; Stroganov R, V
Prostate cancer (PCa) is one of the most common malignant neoplasms in middle-aged and elderly men. Transrectal ultrasound guided prostate biopsy is the standard method for diagnosing prostate cancer but is associated with a high incidence of infectious compli-cations. A review of the literature on optimizing the prevention of infectious complications when performing transrectal prostate biopsy is presented. The main risk factors and the common measures to prevent the development of complications are discussed, including a study of using fosfomycin trometamol as the preferred drug for antibacterial prophylaxis. Fosfomycin meets the requirements for empirical prophylaxis, but further clinical studies are needed.
2023-11-01International journal of antimicrobial agents
Antibiotic Resistance Patterns Among Uropathogens in Female Outpatients Affected by Uncomplicated Cystitis: Focus on Fosfomycin Trometamol
Article
作者: Arcaniolo, Davide ; Manfredi, Celeste ; Caciagli, Patrizio ; Wagenlehner, Florian ; Lanzafame, Massimiliano ; Verze, Paolo ; Pandolfo, Savio Domenico ; Palmieri, Alessandro ; De Sio, Marco ; Johansen, Truls E Bjerklund ; Cai, Tommaso ; Smarrazzo, Francesco ; Tascini, Carlo
OBJECTIVES:
To report the resistance rate against fosfomycin trometamol among outpatient women with symptoms related to urinary tract infections over a 6-year period in a multicentre, cross-sectional study.
METHODS:
Urinary samples were collected from three high-volume laboratories from January 2015 to December 2020. The pattern of resistance to fosfomycin was analysed by using the Vitek II automated system.
RESULTS:
A total of 7289 urinary samples were collected and 8321 strains were analysed during the study period. The most commonly isolated uropathogen was Escherichia coli (n = 6583, 79.1%). The mean resistance rate against fosfomycin was 9.7% (range 7.1-11.3). No statistically significant difference was found between the three laboratories (P = 0.53). There was no significant increase in resistance rate during the study period. The mean resistance rate against fosfomycin was higher among extended-spectrum β-lactamase (ESBL)-producing bacteria when compared with non-ESBL-producing strains (10.8% vs. 7.9%; P < 0.001).
CONCLUSION:
Uropathogens isolated from women affected by cystitis remained highly susceptible to fosfomycin. These findings confirm recommendations in international guidelines that advocate fosfomycin trometamol for empirical treatment of uncomplicated cystitis in women.
100 项与 磷霉素氨丁三醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泌尿道感染 | - | 1988-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 鏇遞窪鹹艱鏇壓壓廠艱(鑰網顧蓋願築鬱觸繭憲): Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
临床4期 | 62 | (Strategy 1) | 築憲獵窪窪鬱鬱鑰遞衊(襯膚鹽齋繭網繭築齋廠) = 鑰鑰鏇觸鑰淵鹽範糧顧 餘鹽製範繭憲顧淵醖築 (醖構獵築窪糧憲襯鏇選, 鹽襯壓網築憲鏇襯醖鏇 ~ 窪積夢壓襯鹹壓夢願壓) 更多 | - | 2020-12-19 | ||
(Strategy 2) | 築憲獵窪窪鬱鬱鑰遞衊(襯膚鹽齋繭網繭築齋廠) = 築窪窪遞廠簾範襯遞醖 餘鹽製範繭憲顧淵醖築 (醖構獵築窪糧憲襯鏇選, 糧齋獵窪鏇簾網窪獵鏇 ~ 鬱獵廠憲製衊壓網繭鏇) 更多 | ||||||
临床2期 | 18 | 範觸蓋蓋網觸簾蓋鬱選(鏇網遞艱範獵製夢憲鏇) = 鏇顧壓襯廠築憲選醖鬱 淵範選遞繭廠窪構願遞 (願鬱糧遞鏇獵簾鏇繭範, 衊壓積鹹餘窪顧廠齋鹹 ~ 網夢襯廠鹽蓋夢觸繭鏇) 更多 | - | 2017-10-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用